🐻 NKE $8.6M Short LEAPS Call Alert — 10,000 Contracts Sold OTM on a 9-Year Low!

📅 April 1, 2026 | 🔥 Extremely Unusual Institutional Short Premium Alert

---

🎯 The Quick Take

Someone just sold 10,000 LEAPS call contracts on Nike expiring December 2027 — a single-session premium haul of $8.6 million — with the stock sitting at a fresh 9-year low of $45.21 the same day it crashed 11%+ on brutal Q4 guidance. This is a textbook short LEAPS call (STO) play: collecting massive upfront premium and betting that Nike stays below $47.50 for the next 20 months. The z-score came in at 795.87 — Extremely Unusual against an open interest of just 43 contracts. Someone built a position that is 232x the existing open interest in one clip. This is not a routine hedge — this is a conviction trade in a stock that is already down 44% from its 52-week high and hitting lows not seen since 2015.

---

📊 Company Overview

Nike, Inc. (NKE) is the world's largest athletic footwear and apparel brand:

• Market Cap: ~$55B (April 1, 2026 — down from ~$76B just days ago post-earnings crash)
• Industry: Footwear / Athletic Apparel
• Current Price: $45.21 (April 1, 2026 — a 9-year low, down 11%+ on the session)
• 52-Week High: $80.17 | 52-Week Low: $47.85 (set intraday today — NKE actually closed lower)
• YTD Performance: Down ~24% from ~$63 at the start of 2026; down ~30% over 3 months
• Dividend Yield: ~3.10% ($1.64/share annually)
• Forward P/E: ~34x (expensive for a company with declining revenue and compressing margins)

Nike is in the middle of a CEO-led turnaround under Elliott Hill, whose "Win Now" strategy has produced early green shoots in North American wholesale (+11% in Q3 FY2026) but faces severe structural headwinds: Greater China revenue is falling off a cliff (-7% Q3, guided -20% Q4), tariffs are costing an estimated $1.5B annually, and competitors On Running, Hoka, and Adidas are actively taking share while Nike resets its channel and assortment. Q3 FY2026 earnings reported March 31, 2026 beat estimates on revenue and EPS, but Q4 guidance crushed the stock — the company guided revenue down 2-4%, well below Wall Street's $11.24B consensus.

---

💰 The Option Flow Breakdown

📊 The Tape (April 1, 2026)

Total Unusual Flow: $8.6M

Signal Classification:

• 🔥 Z-Score: 795.87 — EXTREMELY UNUSUAL
• 📊 Vol/OI Ratio: 232.56 — HIGH ACTIVITY (10,000 contracts vs. just 43 OI)
• 📋 Order Type: STO (Sell to Open — new short position initiated)
• ✅ Has History: True (repeat actor in NKE options flow)
• 🎯 Strategy: STANDALONE (no paired legs detected in session)

---

🤓 What This Actually Means

Real talk: This trader sold 10,000 call contracts — representing 1,000,000 shares of NKE exposure — and collected $8.55 per contract, or $8.55 million in upfront premium, right as the stock was printing 9-year lows.

Here is the math that matters:

• Strike Price: $47.50
• Spot at Trade: $45.21
• OTM Buffer: +$2.29 (the stock needs to rally 5.1% just to reach the strike)
• Premium Collected: $8.55 per contract ($855,000 per 100 contracts, $8.55M total)
• Breakeven for the seller: $47.50 + $8.55 = $56.05 (NKE would need to trade above $56.05 by December 17, 2027 for this trade to lose money)
• Current price distance to breakeven: The stock needs to rally +24% from current levels to threaten the position
• Time to expiration: ~627 days (approximately 20 months)
• Max Profit: $8.55M (full premium collected if NKE closes at or below $47.50 at December 17, 2027 expiration)
• Max Loss: Theoretically unlimited to the upside (though practically capped if NKE recovers meaningfully)

Translation: This seller is betting that Nike does NOT recover to $56+ over the next 20 months. Given the stock is at a 9-year low and down ~44% from its 52-week high of $80.17, that is a bet on prolonged stagnation or continued weakness — not necessarily a crash, just "no recovery."

What makes this unusual beyond the size:

The existing open interest on this specific strike/expiration combination was only 43 contracts. The seller created a position that is 232 times larger than all existing open interest. This is not someone rolling an existing position or scaling into a known strike — this is a fresh, decisive institutional statement built in a single print. The MID execution (neither bid nor ask — at the theoretical midpoint) suggests the seller negotiated directly with a counterparty, likely through a block trade facility, confirming institutional size and purpose.

Why sell calls on a stock that just crashed?

Two scenarios explain this trade:

1. Pure short premium / income play: The seller believes NKE's implied volatility is elevated post-earnings (it almost certainly is — stocks that drop 11% in a day see IV spike dramatically), making LEAPS calls unusually expensive. Selling expensive premium on a stock the seller already believes will not recover is a textbook "sell the panic IV" strategy. With 20 months of theta decay working in the seller's favor, even modest sideways action generates the full $8.55M.

2. Covered call overlay on existing long position: A large institutional holder of NKE stock (long 1,000,000 shares at a significant loss) could be selling these calls as a covered call against their position, generating $8.55M in income to partially offset losses or reduce their cost basis. The long holder's effective exit price would be $47.50 + $8.55 = $56.05 — still well below where they likely bought the stock, but a way to harvest premium while they wait for the stock to stabilize.

Either interpretation is bearish in nature: the seller does not expect NKE to reach $47.50 cleanly in the next 20 months, let alone recover to $80.

---

📈 Technical Setup / Chart Check-Up

YTD Performance Chart

NKE has been in a relentless downtrend throughout 2026. Starting the year near $63, the stock shed ~30% in just three months to reach today's levels around $44-45, making this one of the worst-performing large-cap consumer stocks in the S&P 500 YTD. Today's post-earnings flush accelerated the breakdown to levels not seen since approximately 2015, stripping away a decade of market cap gains. The chart tells a story of a company in genuine fundamental distress — not a temporary pullback.

Key observations:

• 📉 Sustained downtrend: No meaningful bounce attempts have held — each rally fades and the stock makes a lower low
• 🔵 No technical support visible above $40: The chart vacuum below $47 is stark — there are no historic consolidation zones to cushion further selling until the $38-40 area
• ⚠️ Sharply below all key moving averages: The 50-day, 100-day, and 200-day MAs are all well above current price, serving as resistance rather than support
• 📊 Capitulation volume today: The 11%+ drop on Q4 guidance day arrived on extreme volume — historically, peak-volume down days on major earnings disappointments can mark intermediate-term lows, but the guidance picture is too uncertain to call a bottom here with confidence

---

🔵🟠 Gamma-Based Support & Resistance Analysis

Current Price: $44.74

The gamma exposure map reveals precisely where market maker hedging activity is concentrated — and the picture for NKE is dominated by net bearish gamma at virtually every strike level.

🔵 Support Levels (Put Gamma Below Price):

The net GEX bias across all support levels is deeply negative, which means put gamma dominates — market makers are net long puts at these strikes and will sell the underlying as price approaches them, acting as an accelerant to downside rather than a cushion. There is no strong "gamma floor" in the traditional sense — the support levels below are more likely to act as speed bumps than walls.

🟠 Resistance Levels (Call Gamma Above Price):

The most important observation: The $47.50 strike — the exact strike sold in today's LEAPS trade — sits at a significant resistance cluster with 4.37B in total GEX and deeply negative net GEX (-3.72B). This means market makers holding short calls at $47.50 will sell NKE stock aggressively as the price approaches that level, creating a natural cap. The LEAPS seller appears to have deliberately targeted a strike that is already reinforced by structural gamma resistance.

What the gamma map tells us:

The overall GEX summary shows total put gamma (90.87B) vastly exceeding call gamma (30.56B) — a ratio of roughly 3:1 in favor of puts. The net GEX bias is classified as Bearish. The strongest resistance sits at $45 (immediately above current price, at 14.36B total GEX), creating a near-term ceiling that will be very difficult to break cleanly. The stock is effectively trapped under gamma resistance while sitting on a bearish gamma floor that accelerates rather than dampens downside moves.

The LEAPS call seller at $47.50 has the gamma map working entirely in their favor.

---

📐 Implied Move Analysis

Options market pricing for upcoming expirations (Spot: $44.67):

Critical observations for the LEAPS trade:

The LEAPS expiration on December 17, 2027 sits beyond the data in today's implied move grid, but we can extrapolate meaningfully: by March 2027 (352 days), the options market is pricing an upper implied move range of $56.33. The LEAPS call seller collected $8.55 at the $47.50 strike, meaning the breakeven is $56.05 — almost exactly at the 1-year LEAPS implied move upper bound.

This is not a coincidence. The seller has effectively sold the "tail" of the implied move distribution — collecting premium that prices in the probability of NKE reaching $56+, while betting that the options market has overstated that probability. Given the fundamental backdrop (China guidance -20%, tariff headwinds, competitors gaining share), the seller appears to have substantial conviction that $56 is a ceiling, not a target.

The April 17 implied move context: The options market is pricing ±5.45% for April OPEX (16 days), putting the upper bound at just $47.10. That means even the near-term implied move barely reaches the $47.50 strike sold in today's LEAPS trade. The LEAPS seller has multiple layers of protection stacked in their favor.

---

🎪 Catalysts

🔥 Recent Catalysts (Already in the Price — April 1, 2026)

Q3 FY2026 Earnings (Reported March 31, 2026) — The Trigger:

The beat-and-miss combination was brutal: Q3 numbers actually came in better than expected, but the Q4 guidance of revenue down 2-4%, Greater China sales guided -20%, and gross margin pressure from ~250 bps of tariff impact crushed the stock -11%+ on April 1. This was not an earnings miss — it was a forward guidance disaster.

Post-Earnings Analyst Actions:

• Goldman Sachs: Downgraded to Neutral, new PT $52
• Bank of America: Downgraded to Neutral, new PT $55 (from $73)
• Jefferies: Price target cut
• Evercore ISI: Price target cut
• Consensus PT: ~$73 (reflecting significant upside estimates, but the gap to consensus is a function of how badly the stock has been de-rated, not how bullish the street actually is)

Structural Headwinds Already Embedded:

• 🌏 Greater China freefall: 7 consecutive quarters of declining China revenue; Q4 guided -20%. New China head (Cathy Sparks, 25-year Nike veteran) took over March 31 — no quick fix expected
• 💸 Tariff impact: ~$1.5B annually (up from prior $1B estimate), with Vietnam sourcing (20% tariff) representing a structural, not transitory, cost
• 🏃 Competitive erosion: On Running and Hoka taking measurable share in performance running among Nike's core younger demographic; Adidas aggressively targeting U.S. market share during Nike's reset
• 📉 Digital collapse: Nike Direct revenue -4%; digital revenues -9% — the DTC-first strategy reversal is painful
• 💰 Dividend payout ratio >100% in 2026 — sustainability questions beginning to emerge

---

📅 Upcoming Catalysts (Next 20 Months — Through Dec 2027 Expiration)

1. Q4 FY2026 Earnings — June 25, 2026

This is the most critical near-term event. Consensus is anchored to company guidance of ~$10.77B revenue and $0.19 EPS — already dramatically below prior expectations. The key questions:

• Does Greater China actually hit -20% or does it come in even worse?
• Can gross margins stabilize despite 250 bps of tariff drag?
• Does North America wholesale momentum (+11% in Q3) persist through Q4?
• What is the first look at FY2027 guidance?

A miss-and-guide-lower here could send NKE materially below $40. An inline or slight beat might bounce the stock temporarily, but the structural headwinds likely cap any rally.

2. Nike Investor Day — Fall 2026 (Date TBD)

This is potentially the biggest single catalyst for or against the LEAPS short call position. Management plans to present a comprehensive long-term strategic roadmap and full FY2027 guidance from Phil H. Knight Campus in Beaverton, Oregon. If Elliott Hill delivers a credible multi-year margin recovery framework with realistic China stabilization targets, this could be the stock's re-rating moment. If the Investor Day disappoints, NKE risks another leg lower.

The LEAPS seller's risk: A compelling Investor Day with bold FY2027 guidance could push NKE back toward $55-60. That is within the $56.05 breakeven zone. The seller needs the Investor Day to be "good but not great" — enough to stabilize the stock but not enough to ignite a recovery.

3. FY2027 Guidance (Expected June/Fall 2026)

First clean year under Hill's strategy after "Win Now" cleanup completes. Consensus expects a return to positive revenue growth. The question is magnitude — mid-single-digit growth would be a very different stock story than high-single-digit recovery.

4. FIFA Club World Cup — June-July 2026

Major international soccer marketing event. Nike is deeply embedded in the global football (soccer) ecosystem. Strong activation around this event could boost brand sentiment, particularly in markets where China concerns do not dominate the narrative.

5. Back-to-School 2026 (August-September 2026)

First full back-to-school season under the refreshed assortment and channel reset. Failure to show improvement here would signal the turnaround is materially stalling. This is the most practical "ground truth" test of whether the wholesale rebuild is working.

6. Tariff/Trade Policy Wild Card

Any meaningful U.S.-China trade de-escalation would dramatically change the cost structure and China revenue picture simultaneously. This is a low-probability but high-impact event that the LEAPS seller must respect as a tail risk.

---

🎲 Price Targets & Probabilities

The LEAPS call seller profits as long as NKE remains below $56.05 (strike + premium) at December 17, 2027 expiration. Here is how the scenarios map out:

🚀 Bull Case (20% probability) — LEAPS Seller Loses

Target: $58-80+ by December 2027

• Elliott Hill's turnaround inflects dramatically by fall 2026 Investor Day
• Greater China stabilizes faster than expected under new leadership
• Trade policy de-escalation eliminates ~$1.5B tariff headwind
• On/Hoka/Adidas competitive threat proves manageable; Nike regains share in running
• NKE recovers to $58+ (above the $56.05 breakeven) and the LEAPS short call is a loss
• At $80 (52-week high), the LEAPS short call would show a mark-to-market loss of roughly $32-35 per contract

What needs to happen: Essentially everything has to go right simultaneously — China recovery, tariff relief, competitive stabilization, and product cycle success. The consensus analyst PT of $73 is technically consistent with this scenario, but the 34x forward P/E on a declining-revenue company suggests the current consensus is too optimistic.

⚖️ Base Case (50% probability) — LEAPS Seller Wins

Target: $40-55 range through 2027

• NKE stabilizes in the $40-55 range as the turnaround continues grinding forward
• Q4 FY2026 earnings in-line with bearish guidance; FY2027 shows modest recovery
• China remains a headwind but stabilizes at -10 to -15% rather than deteriorating further
• Tariff headwinds persist but company adapts through sourcing shifts and price increases
• Dividend maintained (provides a floor), but stock struggles to sustainably clear $50
• LEAPS call seller collects the full $8.55M at expiration — maximum profit

Why this is most likely: The structural headwinds (China, tariffs, competitive erosion) are multi-year realities, not quarter-to-quarter noise. The channel reset and assortment refresh take 2-3 years to fully rebuild — Hill himself acknowledged the turnaround is "taking longer than I would like." Institutional investors are net sellers. The stock has a 34x forward P/E for a company with declining revenue — even a "good" 2027 outcome may not re-rate the multiple significantly.

🐻 Bear Case (30% probability) — LEAPS Seller Wins Big

Target: $25-40 by December 2027

• Greater China continues deteriorating; Anta/Li Ning entrench further
• Dividend cut becomes necessary as payout ratio exceeds 100% and cash flow deteriorates
• Turnaround stalls or fails; Elliott Hill departs
• Macro recession hits discretionary consumer spending, compressing NKE further
• Stock tests historical decade-lows; LEAPS seller collects full premium, position is deeply profitable
• Note: At $35, LEAPS seller's $8.55 premium represents a ~19% annualized return on a cash-secured basis

What needs to happen: At least two or three of the current headwinds worsen simultaneously. The dividend cut is the most visible trigger — once that happens, the income-buyer floor disappears and the stock re-rates to a pure turnaround multiple with no yield support.

---

💡 Trading Ideas

🛡️ Conservative — "Synthetic Income With a Safety Net"

Strategy: Cash-Secured Short Call at a higher strike

• Sell the NKE Dec 2027 $52.50 Call (~$6-7 estimated premium)
• Cost/collateral: ~$4,500-5,000 in cash or NKE shares per contract as margin
• Max Profit: Full premium collected if NKE stays below $52.50 at expiration
• Breakeven: ~$58.50-59.50 on the upside — requires a 30%+ rally to threaten the position
• Why this works: Selling at a higher strike gives more OTM buffer than today's institutional trade, at the cost of slightly less premium. You're collecting elevated post-earnings IV while betting on continued weakness or stagnation in NKE. The gamma map shows $50 and $52.50 as heavy resistance strikes — the structural headwinds make these ceilings meaningful.

Best for: Investors who want income from elevated IV but with more strike distance from current price.

---

⚖️ Balanced — "The Covered Call Overlay"

Strategy: Sell short-dated monthly calls against an existing NKE position (or newly initiated small long)

• Buy 100 shares of NKE at ~$45 (defining a small long position)
• Sell the May 15 $47 Call (~$2.00-2.50 estimated premium)
• Effective cost basis reduction: ~$42.50-43.00 after premium
• If called away at $47: Total return ~5-6% in 44 days (annualized ~40-50%)
• If not called: Keep rolling calls monthly, further reducing cost basis
• Why this works: You're doing exactly what the LEAPS seller may be doing, but at shorter duration with more frequent premium capture. At $45, the 3.10% dividend yield provides a floor while you sell premium against potential recovery. The gamma map shows $47-47.50 as a natural resistance cluster — selling calls right into that wall is the optimal covered call strike.

Best for: Investors with a long-term bullish view on the Nike brand who want income while waiting for the turnaround to materialize.

---

🚀 Aggressive — "Fade the Recovery Thesis"

Strategy: Bear Put Spread targeting continued weakness

• Buy the NKE June 19, 2026 $45 Put (~$5-6 estimated premium)
• Sell the NKE June 19, 2026 $38 Put (~$2-3 estimated premium)
• Net Cost: ~$3 per spread (debit)
• Max Profit: $7 per spread (if NKE closes below $38 at June Triple Witch) — 2.3x return
• Max Loss: $3 (premium paid) — 100% of net premium
• Breakeven: $42.00 on the downside
• Why this works: Q4 FY2026 earnings (June 25) are the next major binary event. Guidance is already dire (-20% China, -2 to -4% total revenue), and any deterioration beyond guidance could push NKE toward $38-40. The bear put spread lets you capitalize on continued downside with defined risk. The lower range on the June implied move grid is $40.25 — the $38 short put sits just below that, maximizing the probability of keeping the spread premium.

Risk: If NKE stabilizes or bounces into June on any positive catalyst (trade policy news, short squeeze), you lose 100% of the debit. Keep position sizing small — 1-2% of portfolio maximum.

Best for: Traders who believe the June earnings will be another negative catalyst and want asymmetric downside exposure with defined risk.

---

⚠️ Risk Factors

What could turn the LEAPS short call position into a significant loss:

😰 U.S.-China trade de-escalation: If the Trump administration reaches a trade agreement with China in the next 12-18 months, Nike's $1.5B tariff headwind largely disappears and China revenue could recover faster than expected. A trade deal is low probability but extremely high impact — NKE could gap 20%+ on this news alone.

😰 Unexpectedly strong Investor Day (Fall 2026): If Elliott Hill delivers a compelling multi-year financial framework showing 2027 margin recovery to 45%+ gross margins and mid-single-digit revenue growth, institutional investors could aggressively re-rate the stock. A re-rating toward 25x forward earnings on recovering profitability could push NKE to $55-65.

😰 Acquisition premium / buyout: At $45 and a $55B market cap, Nike is cheaper than it has been in a decade relative to its brand value. A strategic acquirer (luxury conglomerate, private equity, or activist-led buyout) could place a bid at a significant premium to current prices, instantly making the $47.50 strike in the money.

😰 Unlimited loss exposure: Unlike a put, a short call has theoretically unlimited risk to the upside. If NKE somehow traded to $80 by December 2027 (its 52-week high), the mark-to-market loss on 10,000 contracts would approach $32M+. This is why this trade demands careful position sizing and potentially a long call hedge above $60-65 as catastrophic risk management.

😰 Short squeeze mechanics: With institutional sellers dominating the flow and sentiment deeply negative, NKE is technically set up for a violent short squeeze if any positive catalyst emerges. Short squeezes move far faster than fundamental analysis would suggest — a 20-25% move in a week is possible if the right catalyst hits.

😰 Dividend sustainability: The 3.10% yield is providing a floor bid from income investors. If NKE cuts the dividend (payout ratio already exceeds 100%), income sellers would accelerate the decline — but this would also paradoxically reduce the upside risk to the LEAPS seller by further demoralizing the stock.

---

🎯 The Bottom Line

Real talk: Someone with very deep pockets and very high conviction walked in on the single worst trading day for NKE in years — a fresh 9-year low, -11% on the session, Goldman and BofA both downgrading — and sold $8.6 million worth of calls set to expire 20 months from now. They built a position 232x the existing open interest in a single print. That is not a hedge. That is a declaration.

The thesis is simple: Nike does not recover to $56+ by December 2027. Given the structural weight of Greater China deterioration, $1.5B in tariff headwinds, competitive erosion from On and Hoka, a turnaround that management itself says is "taking longer than I would like," and a forward P/E of 34x on declining revenue — that is not an outlandish bet. The gamma map has $47.50 reinforced as structural resistance. The implied move grid shows the 1-year upper bound barely clears $56. The seller appears to have done their homework.

Here is the deal for different scenarios:

• ✅ If you're bearish NKE (aligned with the institutional flow): The LEAPS short call thesis is well-constructed. Consider smaller-scale analogues: covered calls on any existing long position at the $47-47.50 strike, or bear put spreads into the June Q4 earnings event (June 25). The gamma resistance at $45 and $47.50 means any rally is likely to stall.
• 👀 If you're watching from the sidelines: Mark your calendar for June 25 (Q4 FY2026 earnings) and the Fall 2026 Investor Day. These are the two binary events that will determine whether the turnaround is real or a value trap. The $45 level is your current line in the sand — if the stock stabilizes here, the income play on covered calls is compelling. If $45 breaks cleanly on volume, the $40 area is the next meaningful level.
• 🚀 If you're contrarian bullish: The 52-week high of $80.17 and analyst consensus PT of $73 technically offer massive upside. CEO insider buying at $61.10, $9B+ in liquidity, and a confirmed Investor Day suggest the bull case is not dead. But you need to be comfortable holding through continued fundamental deterioration for potentially 12-18 months before the turnaround inflects. If you go long here, sell covered calls at $47-50 against your position and collect premium while you wait — it's free money in a stock that the gamma map shows will struggle to clear that level.

Mark your calendar for: June 25 (Q4 FY2026 earnings), Fall 2026 Investor Day (exact date TBD), and December 17, 2027 (LEAPS expiration — the final verdict on whether this $8.6M bet was genius or hubris).

When a single trader sells $8.6M in LEAPS calls with a z-score of 795 on the day a stock hits a 9-year low, they are not guessing. Watch this one closely. 💪

---

⚠️ Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial advice. Options trading involves substantial risk of loss and is not suitable for all investors. Selling uncovered or naked call options carries theoretically unlimited risk and may result in losses far exceeding the premium collected. Margin requirements for short options positions can be substantial. Always consult a qualified financial advisor before making investment decisions. Past unusual options activity does not guarantee future price movements.